Oxaprozin

Oxaprozin is an orally active and potent COX inhibitor, with IC50 values of 2.2 μM for human platelet COX-1 and and 36 μM for IL-1-stimulated human synovial cell COX-2, respectively. Oxaprozin also inhibits the activation of NF-κB. Oxaprozin induces cell apoptosis. Oxaprozin shows anti-inflammatory activity. Oxaprozin-mediated inhibition of the Akt/IKK/NF-κB pathway contributes to its anti-inflammatory properties[1][2].

Product Specifications

CAS Number

[21256-18-8]

Product Name Alternative

Oxaprozinum; Wy21743

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Akt; Apoptosis; COX; IKK; NF-κB

Type

Reference compound

Related Pathways

Apoptosis; Immunology/Inflammation; NF-κB; PI3K/Akt/mTOR

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cancer

Assay Protocol

https://www.medchemexpress.com/Oxaprozin.html

Purity

99.94

Solubility

DMSO : ≥ 100 mg/mL

Smiles

O=C(O)CCC1=NC(C2=CC=CC=C2)=C(C3=CC=CC=C3)O1

Molecular Formula

C18H15NO3

Molecular Weight

293.32

Precautions

H302, H315, H319, H335

References & Citations

[1]Ottonello L, et al. Delayed apoptosis of human monocytes exposed to immune complexes is reversed byoxaprozin: role of the Akt/IkappaB kinase/nuclear factor kappaB pathway. Br J Pharmacol. 2009 May;157 (2) :294-306.|[2]Montecucco F, et al. Oxaprozin-induced apoptosis on CD40 ligand-treated human primary monocytes is associated with the modulation of defined intracellular pathways. J Biomed Biotechnol. 2009;2009:478785.